Determination of anti-Müllerian hormone in women

Česká verzia

Authors: R. Kučera ¹; O. Topolčan ¹; T. Rumpíková ²; D. Rumpík ²; J. Dostál ³
Authors place of work: Imunoanalytická laboratoř ONM Fakultní nemocnice, Plzeň, vedoucí pracoviště prof. MUDr. O. Topolčan, CSc. ¹; Klinika reprodukční medicíny a gynekologie, Zlín, vedoucí pracoviště prof. MUDr. L. Pilka, DrSc. ²; Porodnicko-gynekologická klinika FN a LF UP, Olomouc, přednosta prof. MUDr. R. Pilka, Ph. D. ³
Published in the journal: Ceska Gynekol 2013; 78(3): 282-288

Summary

Anti-Müllerian hormone (AMH) is a glycoprotein and belongs to the TGF-β growth factors family. Our review describes the method of AMH determination in serum and follicular fluid. The reference values and changes in AMH levels during a woman‘s life are also discussed. In addition, it is also presented the relationship between AMH, obesity, smoking and use of hormonal contraceptives. The focus of the work is the importance of the determination of AMH in clinical practice. In assisted reproduction has become its determination one of the tools to detect ovarian reserve. It helps not only predict reduced response to stimulation with gonadotropins but also the risk of the ovarian hyperstimulation syndrome. Benefits of the ovarian reserve detection using AMH serum levels are discussed in comparison with the antral follicle count (AFC) determined by ultrasound. Several clinical indications of AMH determination are mentioned in the next section. These are primarily the polycystic ovary syndrome (PCOS), which is a great challenge not only for the AMH testing, but there is an open space for further interdisciplinary cooperation. Endometriosis has no direct effect on ovarian reserve and AMH levels in serum. AMH is very sensitive tumor marker in the diagnostics and monitoring of ovarian granulosa cells tumors. Treatment of cancer disease burdens entire body, including healthy cells. Ovarian follicles are very sensitive to chemotherapy and radiation. AMH is a good predictor of ovarian reserve damage during radio- and chemotherapy.

Keywords:
AMH – ART – antral follicle count – endometriosis – chemotherapy – IVF – granulosa cell tumor – OHSS – PCOS

Zdroje

1. Baker, ML, Metcalfe, SA, Hutson, JM. Serum levels of müllerian inhibiting substance in boys from birth to 18 years, as determined by enzyme immunoassay. J Clin Endocrinol Metab, 1990, 70, 1, p. 11–15.

2. Bentzen, JG., Forman, JL., Pinborg, A., et al. Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception. Reprod Biomed Online, 2012, 25, 6, p. 612–619.

3. Carlsen, SM., Vanky, E., Fleming, R. Anti-Müllerian hormone concentrations in androgen suppressed women with polycystic ovary syndrome. Hum Reprod, 2009, 24, 7, p. 1732–1738.

4. Celik, HG., Dogan, E., Okyay, E., et al. Effect of laparoscopic excision of endometriomas on ovarian reserve: serial changes in the serum antimüllerian hormone levels. Fertil Steril, 2012, 97, 6, p. 1472–1478.

5. Deb, S., Campbell, BK., Pincott-Allen, C., et al. Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti-Müllerian hormone and small antral follicle count using three-dimensional ultrasound. Ultrasound Obstet Gynecol, 2012, 39, 5, p. 574–580.

6. de Vet, A., Laven, JS., de Jong, FH., Themmen, AP.,Fauser, BC. Anti-Müllerian hormone serum levels: A putative marker for ovarian aging. Fertil Steril, 2002, 77, 2, p. 357–362.

7. Dillon, KE., Sammel, MD., Prewitt, M., et al. Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril, 2012, 12, 2, p. 2258–2263.

8. Durlinger, AL., Gruijters, MJ., Kramer, P., et al. Anti-müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology, 2001, 142, 11, p. 4891–4899.

9. Durlinger, AL., Kramer, P., Karels, B., et al. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology, 1999, 140, 12, p. 5789–5796.

10. Falbo, A., Rocca, M., Russo, T., et al. Serum and follicular anti-Müllerian hormone levels in women with polycystic ovary syndrome (PCOS) under metformin. J Ovarian Res, 2010, 21, p. 3–16.

11. Fanchin, R., Mendez Lozano, DH., Frydman, N., et al. Anti-Müllerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab, 2007, 92, 5, p. 1796–1802.

12. Fanchin, R., Schonäuer, LM., Righini, C., et al. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod, 2003, 18, 2, p. 323–327.

13. Freour, T., Masson, D., Dessolle, L., et al. Ovarian reserve and in vitro fertilization cycles outcome according to women smoking status and stimulation regimen. Arch Gynecol Obstet, 2012, 285, 4, p. 1177–1182.

14. Fuentes, A., Muñoz, A., Pommer, R., et al. Decreased anti-Müllerian hormone concentration in follicular fluid of female smokers undergoing artificial reproductive techniques. Chemosphere, 2012, 88, 4, p. 403–406.

15. Gleicher, N., Weghofer, A., Barad, DH. Can egg donor selection be improved? A pilot study. Reprod Biol Endocrinol, 2010, 24, 8, p. 76.

16. Gracia, CR., Sammel, MD., Freeman, E., et al. Impact of cancer therapies on ovarian reserve. Fertil Steril, 2012, 97, 1, p. 134–140.

17. Halawaty, S., ElKattan, E., Azab, H., et al. Effect of obesity on parameters of ovarian reserve in premenopausal women.J Obstet Gynaecol Can, 2010, 32, 7, p. 687–690.

18. Hart, R., Doherty, D., Norman, R., et al. Serum anti-Müllerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Feril Steril, 2010, 94, 3, p. 1118–1121.

19. Healy, DL., Burger, HG., Mamers, P., et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med, 1993, 329, 21, p. 1539–1542.

20. Hendriks, DJ., Mol, BW., Bancsi, LF., et al. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril, 2005, 83, 2, p. 291–301.

21. Hudson, PL., Dougas, I., Donahoe, PK., et al. An immunoassay to detect human müllerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab, 1990, 70, 1, p. 16–22.

22. Jonard, S., Dewailly, D. The follicular excess in polycystic ovaries, due to ovarian hyperandrogenism, may be the culprit for the follicular arrest. Hum Reprod Update, 2004, 10, 2, p. 107–117.

23. Josso, N., Legeai, L., Forest, MG., et al. An enzyme linked immunoassay for anti-müllerian hormone: a new tool for the evaluation of testicular function in infants and children. J Clin Endocrinol Metab, 1990, 70, 1, p. 23–27.

24. Karkanaki, A., Vosnakis, C., Panidis, D. The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology. Hormones, 2011, 10, 2, p. 95–103.

25. Kelsey, TW., Wright, P., Nelson, SM., et al. A validated model of serum anti-müllerian hormone from conception to menopause. PLoS One, 2011, 6, 7, p. 22024.

26. La Marca, A., Sighinolfi, G., Radi, D., et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update, 2010, 16, 2, p. 113–130.

27. La Marca, A., Volpe, A. Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol, 2006, 64, 6, p. 603–610.

28. La Marca, A., Volpe, A. The anti-Mullerian hormone and ovarian cancer. Hum Reprod Update, 2007, 13, 3, p. 265–273.

29. Lane, AH., Lee, MM., Fuller, AF. Jr., et al. Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol, 1999, 73, 1, p. 51–55.

30. Lee, MM., Misra, M., Donahoe, PK., MacLaughlin, DT. MIS/AMH in the assessment of cryptorchidism and intersex conditions. Mol And Cell Biotechnology, 2003, 211, 1–2, p. 91–98.

31. Lee, MM. Reproductive hormones in infant girls–a harbinger of adult reproductive function? J Clin Endocrinol Metab, 2003, 88, 8, p. 3513–3514.

32. Legro, RS., Gnatuk, CL., Kunselman, AR., Dunaif, A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab, 2005, 90, 6, p. 3236–3242.

33. Lekamge, DN., Barry, M., Kolo, M., et al. Anti-Müllerian hormone as a predictor of IVF outcome. Reprod Biomed Online, 2007, 14, 5, p. 602–610.

34. Li, HW., Wong, CY., Yeung, WS., et al. Serum anti-müllerian hormone level is not altered in women using hormonal contraceptives. Contraception, 2011, 83, 6, p. 582–585.

35. Lie Fong, S., Baart, EB., Martini, E., et al. Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality? Reprod Biomed Online, 2008, 16, 5, p. 664–670.

36. Long, WQ., Ranchin, V., Pautier, P., et al. Detection of minimal levels of serum anti-Müllerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab, 2000, 85, 2, p. 540–544.

37. Nakhuda, GS., Douglas, NC., Thornton, MH., et al. Anti-Müllerian hormone testing is useful for individualization of stimulation protocols in oocyte donors. Reprod Biomed Online, 2011, 22, 1, p. 88–93.

38. Nelson, SM., Yates, RW., Fleming, R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles–implications for individualization of therapy. Hum Reprod, 2007, 22, 4, p. 2414–2421.

39. Nelson, SM., Yates, RW., Lyall, H., et al. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009, 24, 4, p. 867–875.

40. Nestler, JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med, 2008, 358, 1, p. 47–54.

41. Norman, RJ., Dewailly, D., Legro, RS., Hickley, T. Polycystic ovary syndrome. Lancet, 2007, 370, 9588, p. 685–697.

42. Pellat, L., Hanna, L., Brinmat, M., et al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab, 2007, 92, 1, p. 240–245.

43. Picard, JY., Josso N. Purification of testicular AMH allowing direct visualization of the pure glycoprotein and determination of the yield and purification factor. Mol Cell Endocrinol, 1984, 34, 1, p. 17–30.

44. Piltonen, T., Morin-Papunen, L., Koivunen, R., et al. Serum AMH levels remain high until late reproductive age and decrease during metformin treatment in women with polycystic ovary syndrome. Hum Reprod, 2005, 20, 7, p. 1820–1826.

45. Piouka, A., Farmakiotis, D., Macut, D., et al. Anti-Müllerian hormone levels are increased in women with classical PCOS and are negatively influenced by obesity. Am J Physiol Endocrinol Metab, 2009, 296, 2, p. 238–243.

46. Polyzos, NP., Stoop, D., Blockeel, C., et al. Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist-treated oocyte donors. Reprod Biomed Online, 2012, 24, 5, p. 532–539.

47. Seifer, DB., MacLaughlin, DT., Christian, BP., et al. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril, 2002, 77, 3, p. 468–471.

48. Practice Committee of American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril, 2008, 90, 5, p. 188–193.

49. Rey, R., Lukas-Croisier, C., Lasala, C., Bedecarras, P. AMH/MIS: what we know already about the gene, the protein and its regulation. Mol And Cell Endocrinol, 2003, 211, 1–2, p. 21–31.

50. Riggs, R., Kimble, T., Oehninger, S., et al. Anti-Müllerian hormone serum levels predict response to controlled ovarian hyperstimulation but not embryo quality or pregnancy outcome in oocyte donation. Fertil Steril, 2011, 95, 1, p. 410–412.

51. Rosen, MP., Johnstone, E., McCulloch, CE., et al. A characterization of the relationship of ovarian reserve markers with age. Fertil Steril, 2012, 97, 1, p. 238–243.

52. Sahmay, S., Usta, T., Erel, CT., et al. Is there any correlation between amh and obesity in premenopausal women? Arch Gynecol Obstet, 2012, 286, 3, p. 661–665.

53. Sir Petermann, T., Conder, T., Mliqueo, M., et al. Increased anti-Müllerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2006, 91, 8, p. 3105–3109.

54. Smeenk, JM., Sweep, FC., Zielhuis, GA., et al. Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracytoplasmic sperm injection. Fertil Steril, 2007, 87, 1, p. 223–226.

55. Sowers, MR., McConnell, D., Yosef, M., et al. Relating smoking, obesity, insulin resistance, and ovarian biomarker changes to the final menstrual period. Ann N Y Acad Sci, 2010, 1204, p. 95–103.

56. Streuli, I., de Ziegler, D., Gayet, V., et al. In women with endometriosis anti-Müllerian hormone levels are decreased only in those with previous endometrioma surgery. Hum Reprod, 2012, 27, 11, p. 3294–3303.

57. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004, 19, 1, p. 41–47.

58. Tummon, I., Gavrilova-Jordan, L., Allemand, MC.,Session, D. Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstet Gynecol Scand, 2005, 84, 7, p. 611–616.

59. van Rooij, IA., Broekmans, FJ., te Velde, ER., et al. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod, 2002, 17, 12, p. 3065–3071.

60. Wunder, DM., Bersinger, NA., Yared, M., et al. Statistically significant changes of antimüllerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. Fertil Steril, 2008, 89, 4, p. 927–933.

61. Weenen, C., Laven, JS., Von Bergh, AR., et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod, 2004, 10, 2, p. 77–83.

62. Yang, YS., Hur, MH., Kim, SY., Young, K. Correlation between sonographic and endocrine markers of ovarian aging as predictors for late menopausal transition. Menopause, 2011, 18, 2, p. 138–145.